Loading...
Market
Will BlueBird Bio's gene therapy for sickle cell disease be administered to more than 100 patients by the end of Q1 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official reports or press releases from BlueBird Bio
Story
12-Year-Old Kendric Cromer Receives $2.2 Million Gene Therapy for Sickle Cell Disease
Sep 16, 2024, 11:50 PM
Kendric Cromer, a 12-year-old boy, has become one of the first children to be treated with a newly approved gene therapy for sickle cell disease. This treatment, developed by BlueBird Bio, offers hope for a cure and a future free from the excruciating pain that has characterized his life. However, the high cost of the treatment, priced at $2.2 million, poses significant challenges. Insurers are hesitant to cover the expense, and hospitals are wary of the financial burden. The approval of this gene therapy by the FDA marks a significant milestone, but accessibility remains a critical issue for many patients. Deepak Srivastava highlights the broader issue of how to pay for breakthrough cures.
View original story
Similar markets
Yes • 50%
No • 50%
Improved survival rates • 25%
Increased cancer rates • 25%
Stable condition • 25%
Other • 25%
Safety warning update • 25%
Clinical trial halt • 25%
No action • 25%
Other action • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
Less than 1% • 25%
1% to 5% • 25%
5% to 10% • 25%
More than 10% • 25%
Yes • 50%
No • 50%
New England Journal of Medicine • 25%
Journal of the American Medical Association • 25%
The Lancet • 25%
Other • 25%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%